MedTrace Logo

Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

NCT03846414 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2019-02-19

No results posted yet for this study

Summary

The aim of this study is to observe and evaluate the cost-effectiveness,efficacy and safety of PEG-rhG-CSF in preventing chemotherapy-induced neutropenia(CIN) of cancer patients in the real world.1000 patients with non-myeloid malignancy who is planned to receive PEG-rhG-CSF for CIN prevention and 500 patients with non-myeloid malignancy who is planned to receive rhG-CSF for CIN prevention or treatment were prospectively recruited.The primary outcome was cost-effectiveness and second outcome was febrile neutropenia,the incidence and duration of grade IV neutropenia,chemotherapy delay,incidence of reduced dose of chemotherapy and relative dose intensity of chemotherapy.

Conditions

  • Chemotherapy-induced Neutropenia
  • Myelosuppression

Interventions

DRUG

PEG-rhG-CSF

PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.

Sponsors & Collaborators

  • CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-13
Primary Completion
2020-04-01
Completion
2020-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03846414 on ClinicalTrials.gov